Bottlenecks in HIV-1 transmission: Insights from the study of founder viruses

Nature Reviews Microbiology

Volumn 13, Issue 7, 2015, Pages 414-425

  Joseph, Sarah B ^a,b   Swanstrom, Ronald ^a,b   Kashuba, Angela D M ^b,c   Cohen, Myron S ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c University of North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTIVE IMMUNITY; BOTTLENECK POPULATION; CONSENSUS SEQUENCE; DISEASE COURSE; DONOR SITE; FOUNDER EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MACROPHAGE; MEN WHO HAVE SEX WITH MEN; NEISSERIA GONORRHOEAE; NEISSERIA MENINGITIDIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; REVIEW; SEXUAL TRANSMISSION; SIMIAN IMMUNODEFICIENCY VIRUS; STREPTOCOCCUS PNEUMONIAE; TARGET CELL; VIRUS ATTACHMENT; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS TRANSMISSION; CD4+ T LYMPHOCYTE; GENETIC SELECTION; GENETICS; GLYCOSYLATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MOLECULAR EVOLUTION; PHYSIOLOGY; TRANSMISSION; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

VIRUS PROTEIN;

CD4-POSITIVE T-LYMPHOCYTES; EVOLUTION, MOLECULAR; GLYCOSYLATION; HIV INFECTIONS; HIV-1; HUMANS; SELECTION, GENETIC; VIRAL PROTEINS;

EID: 84931565184     PISSN: 17401526     EISSN: 17401534     Source Type: Journal    
DOI: 10.1038/nrmicro3471     Document Type: Review

References (126)

1. Derdeyn, C. A. et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303, 2019-2022 (2004).
2. Abrahams, M. R. et al. Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J. Virol. 83, 3556-3567 (2009).
3. Keele, B. F. et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl Acad. Sci. USA 105, 7552-7557 (2008).
4. Haaland, R. E. et al. Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog. 5, e1000274 (2009).
5. Fieni, F. et al. Viral RNA levels and env variants in semen and tissues of mature male rhesus macaques infected with SIV by penile inoculation. PLoS ONE 8, e76367 (2013).
6. Chaillon, A. et al. HIV migration between blood and cerebrospinal fluid or semen over time. J. Infect. Dis. 209, 1642-1652 (2014).
7. Anderson, J. A. et al. HIV-1 populations in semen arise through multiple mechanisms. PLoS Pathog. 6, e1001053 (2010).
8. Boeras, D. I. et al. Role of donor genital tract HIV-1 diversity in the transmission bottleneck. Proc. Natl Acad. Sci. USA 108, E1156-E1163 (2011).
9. Byrn, R. A. & Kiessling, A. A. Analysis of human immunodeficiency virus in semen: indications of a genetically distinct virus reservoir. J. Reprod. Immunol. 41, 161-176 (1998).
10. Delwart, E. L. et al. Human immunodeficiency virus type 1 populations in blood and semen. J. Virol. 72, 617-623 (1998).
11. Diem, K. et al. Male genital tract compartmentalization of human immunodeficiency virus type 1 (HIV). AIDS Res. Hum. Retroviruses 24, 561-571 (2008).
12. Gupta, P. et al. Human immunodeficiency virus type 1 shedding pattern in semen correlates with the compartmentalization of viral quasi species between blood and semen. J. Infect. Dis. 182, 79-87 (2000).
13. Kiessling, A. A. et al. Human immunodeficiency virus in semen arises from a genetically distinct virus reservoir. AIDS Res. Hum. Retroviruses 14, S33-S41 (1998).
14. Overbaugh, J., Anderson, R. J., Ndinya-Achola, J. O. & Kreiss, J. K. Distinct but related human immunodeficiency virus type 1 variant populations in genital secretions and blood. AIDS Res. Hum. Retroviruses 12, 107-115 (1996).
15. Zhu, T. F. et al. Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J. Virol. 70, 3098-3107 (1996).
16. Bull, M. et al. Compartmentalization of HIV-1 within the female genital tract is due to monotypic and low-diversity variants not distinct viral populations. PLoS ONE 4, e7122 (2009).
17. Poss, M. et al. Evolution of envelope sequences from the genital tract and peripheral blood of women infected with clade A human immunodeficiency virus type 1. J. Virol. 72, 8240-8251 (1998).
18. Bull, M. E. et al. Human immunodeficiency viruses appear compartmentalized to the female genital tract in cross-sectional analyses but genital lineages do not persist over time. J. Infect. Dis. 207, 1206-1215 (2013).
19. Bull, M. E. et al. Monotypic human immunodeficiency virus type 1 genotypes across the uterine cervix and in blood suggest proliferation of cells with provirus. J. Virol. 83, 6020-6028 (2009).
20. Roberts, L. et al. Genital tract inflammation during early HIV-1 infection predicts higher plasma viral load set point in women. J. Infect. Dis. 205, 194-203 (2012).
21. Butler, D. M. et al. The origins of sexually transmitted HIV among men who have sex with men. Sci. Transl Med. 2, 18re1 (2010).
22. Heath, L., Frenkel, L. M., Foley, B. T. & Mullins, J. I. Comment on "The origins of sexually transmitted HIV among men who have sex with men". Sci. Transl Med. 2, 50le1 (2010).
23. Gianella, S. et al. Sexual transmission of predicted CXCR4-tropic HIV-1 likely originating from the source partner's seminal cells. Virology 434, 2-4 (2012).
24. Salle, B. et al. Infection of macaques after vaginal exposure to cell-associated simian immunodeficiency virus. J. Infect. Dis. 202, 337-344 (2010).
25. Miller, C. J. et al. Genital mucosal transmission of simian immunodeficiency virus: animal model for heterosexual transmission of human immunodeficiency virus. J. Virol. 63, 4277-4284 (1989).
26. Gnanakaran, S. et al. Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog. 7, e1002209 (2011).
27. Chohan, B. et al. Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J. Virol. 79, 6528-6531 (2005).
28. Sagar, M. et al. Selection of HIV variants with signature genotypic characteristics during heterosexual transmission. J. Infect. Dis. 199, 580-589 (2009).
29. Ping, L. H. et al. Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design. J. Virol. 87, 7218-7233 (2013).
30. Frost, S. D. et al. Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J. Virol. 79, 6523-6527 (2005).
31. Liu, Y. et al. Env length and N-linked glycosylation following transmission of human immunodeficiency virus Type 1 subtype B viruses. Virology 374, 229-233 (2008).
32. Curlin, M. E. et al. HIV-1 envelope subregion length variation during disease progression. PLoS Pathog. 6, e1001228 (2010).
33. Sagar, M., Wu, X., Lee, S. & Overbaugh, J. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J. Virol. 80, 9586-9598 (2006).
34. Russell, E. S. et al. The genetic bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralization-resistant virus from the maternal viral population. J. Virol. 85, 8253-8262 (2011).
35. Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307-312 (2003).
36. West, A. P. et al. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell 156, 633-648 (2014).
37. Wilen, C. B. et al. Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. J. Virol. 85, 8514-8527 (2011).
38. Lavine, C. L. et al. High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeficiency virus type 1 infection. J. Virol. 86, 2153-2164 (2012).
39. Balzarini, J. Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy. Nat. Rev. Microbiol. 5, 583-597 (2007).
40. Ballegaard, V., Haugaard, A. K., Garred, P., Nielsen, S. D. & Munthe-Fog, L. The lectin pathway of complement: advantage or disadvantage in HIV pathogenesis? Clin. Immunol. 154, 13-25 (2014).
41. Adamek, M. et al. Characterization of mannose-binding lectin (MBL) variants by allele-specific sequencing of MBL2 and determination of serum MBL protein levels. Tissue Antigens 82, 410-415 (2013).
42. Wing, J. B. et al. Mannose-binding lectin is present in human semen and modulates cellular adhesion of Neisseria gonorrhoeae in vitro. Clin. Exp. Immunol. 157, 408-414 (2009).
43. Munch, J. et al. Semen-derived amyloid fibrils drastically enhance HIV infection. Cell 131, 1059-1071 (2007).
44. Kim, K. A. et al. Semen-mediated enhancement of HIV infection is donor-dependent and correlates with the levels of SEVI. Retrovirology 7, 1-12 (2010).
45. Roan, N. R. et al. Peptides released by physiological cleavage of semen coagulum proteins form amyloids that enhance HIV infection. Cell Host Microbe 10, 541-550 (2011).
46. Gulick, R. M. et al. Maraviroc for previously treated patients with R5 HIV-1 infection. New Engl. J. Med. 359, 1429-1441 (2008).
47. Zirafi, O. et al. Semen-mediated enhancement of HIV infection markedly impairs the antiviral efficacy of microbicides. AIDS Res. Hum. Retroviruses 30, A183-A183 (2014).
48. Munch, J. et al. Effect of semen and seminal amyloid on vaginal transmission of simian immunodeficiency virus. Retrovirology 10, 1-9 (2013).
49. Cohen, M. S. et al. Prevention of HIV-1 infection with early antiretroviral therapy. New Engl. J. Med. 365, 493-505 (2011).
50. Quinn, T. C. et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. New Engl. J. Med. 342, 921-929 (2000).
51. Baeten, J. M. et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci. Transl Med. 3, 77ra29 (2011).
52. Butler, D. A. et al. Herpes simplex virus 2 serostatus and viral loads of HIV-1 in blood and semen as risk factors for HIV transmission among men who have sex with men. AIDS 22, 1667-1671 (2008).
53. Cohen, M. S. Sexually transmitted diseases enhance HIV transmission: no longer a hypothesis. Lancet 351, 5-7 (1998).
54. Moss, W. J. et al. Suppression of human immunodeficiency virus replication during acute measles. J. Infect. Dis. 185, 1035-1042 (2002).
55. Watt, G., Kantipong, P. & Jongsakul, K. Decrease in human immunodeficiency virus type 1 load during acute dengue fever. Clin. Infect. Dis. 36, 1067-1069 (2003).
56. Anzala, A. O. et al. Acute sexually transmitted infections increase human immunodeficiency virus type 1 plasma viremia, increase plasma type 2 cytokines, and decrease CD4 cell counts. J. Infect. Dis. 182, 459-466 (2000).
57. Cohen, M. S. et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. Lancet 349, 1868-1873 (1997).
58. Malott, R. J. et al. Neisseria gonorrhoeae-derived heptose elicits an innate immune response and drives HIV-1 expression. Proc. Natl Acad. Sci. USA 110, 10234-10239 (2013).
59. Nagot, N. et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. New Engl. J. Med. 356, 790-799 (2007).
60. Nixon, B. et al. Genital herpes simplex virus type 2 infection in humanized HIV-transgenic mice triggers HIV shedding and is associated with greater neurological disease. J. Infect. Dis. 209, 510-522 (2014).
61. Wilen, C. B., Tilton, J. C. & Doms, R. W. in HIV: From Biology to Prevention and Treatment (eds Bushman, F. D., Nabel, G. J. & Swanstrom, R.) (Cold Spring Harbor Laboratory, 2011).
62. Berger, E. A., Murphy, P. M. & Farber, J. M. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17, 657-700 (1999).
63. Johnston, S. H. et al. A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains. J. Virol. 83, 11016-11026 (2009).
64. Joseph, S. B. et al. Quantification of entry phenotypes of macrophage-tropic HIV-1 across a wide range of CD4 densities. J. Virol. 88, 1858-1869 (2014).
65. Parrish, N. F. et al. Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7. PLoS Pathog. 8, e1002686 (2012).
66. Isaacman-Beck, J. et al. Heterosexual transmission of human immunodeficiency virus type 1 subtype C: macrophage tropism, alternative coreceptor use, and the molecular anatomy of CCR5 utilization. J. Virol. 83, 8208-8220 (2009).
67. Li, H. et al. High multiplicity infection by HIV-1 in men who have sex with men. PLoS Pathog. 6, e1000890 (2010).
68. Ochsenbauer, C. et al. Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J. Virol. 86, 2715-2728 (2012).
69. Salazar-Gonzalez, J. F. et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J. Exp. Med. 206, 1273-1289 (2009).
70. Parker, Z. F. et al. Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5. J. Virol. 87, 2401-2411 (2013).
71. Parrish, N. F. et al. Phenotypic properties of transmitted founder HIV-1. Proc. Natl Acad. Sci. USA 110, 6626-6633 (2013).
72. Asmal, M. et al. A signature in HIV-1 envelope leader peptide associated with transition from acute to chronic infection impacts envelope processing and infectivity. PLoS ONE 6, e23673 (2011).
73. Banchereau, J. & Steinman, R. M. Dendritic cells and the control of immunity. Nature 392, 245-252 (1998).
74. Shen, R. et al. Vaginal myeloid dendritic cells transmit founder HIV-1. J. Virol. 88, 7683-7688 (2014).
75. Cameron, P. U. et al. Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells. Science 257, 383-386 (1992).
76. Pope, M. et al. Conjugates of dendritic cells and memory T lymphocytes from skin facilitate productive infection with HIV-1. Cell 78, 389-398 (1994).
77. Kawamura, T. et al. Candidate microbicides block HIV-1 infection of human immature Langerhans cells within epithelial tissue explants. J. Exp. Med. 192, 1491-1500 (2000).
78. Kawamura, T. et al. R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. Proc. Natl Acad. Sci. USA 100, 8401-8406 (2003).
79. Tenner-Racz, K. et al. The unenlarged lymph nodes of HIV-1-infected, asymptomatic patients with high CD4 T cell counts are sites for virus replication and CD4 T cell proliferation, the impact of highly active antiretroviral therapy. J. Exp. Med. 187, 949-959 (1998).
80. van der Ende, M. E. et al. CD4 T cells remain the major source of HIV-1 during end stage disease. AIDS 13, 1015-1019 (1999).
81. Piguet, V. & Steinman, R. M. The interaction of HIV with dendritic cells: outcomes and pathways. Trends Immunol. 28, 503-510 (2007).
82. Zhang, Z. Q. et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science 286, 1353-1357 (1999).
83. Zhang, Z. Q. et al. Roles of substrate availability and infection of resting and activated CD4+ T cells in transmission and acute simian immunodeficiency virus infection. Proc. Natl Acad. Sci. USA 101, 5640-5645 (2004).
84. Li, Q. et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature 458, 1034-1038 (2009).
85. Atashili, J., Poole, C., Ndumbe, P. M., Adimora, A. A. & Smith, J. S. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS 22, 1493-1501 (2008).
86. Freeman, E. E. et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20, 73-83 (2006).
87. Carlson, J. M. et al. HIV transmission. Selection bias at the heterosexual HIV-1 transmission bottleneck. Science 345, 1254031 (2014).
88. Boutwell, C. L. et al. Frequent and variable cytotoxic-T-lymphocyte escape-associated fitness costs in the human immunodeficiency virus type 1 subtype B Gag proteins. J. Virol. 87, 3952-3965 (2013).
89. Martinez-Picado, J. et al. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J. Virol. 80, 3617-3623 (2006).
90. Schneidewind, A. et al. Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J. Virol. 81, 12382-12393 (2007).
91. Allen, T. M. et al. Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J. Virol. 78, 7069-7078 (2004).
92. Leslie, A. J. et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat. Med. 10, 282-289 (2004).
93. Li, B. et al. Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution. J. Virol. 81, 193-201 (2007).
94. Fischer, W. et al. Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. PLoS ONE 5, e12303 (2010).
95. Henn, M. R. et al. Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog. 8, e1002529 (2012).
96. Kijak, G. H. et al. Cryptic multiple HIV-1 infection revealed by early, frequent, and deep sampling during acute infection. AIDS Res. Hum. Retroviruses 30, A58 (2014).
97. Fenton-May, A. E. et al. Relative resistance of HIV-1 founder viruses to control by interferon-α. Retrovirology 10, 146 (2013).
98. Abel, K., Rocke, D. M., Chohan, B., Fritts, L. & Miller, C. J. Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection. J. Virol. 79, 12164-12172 (2005).
99. Sandler, N. G. et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 511, 601-605 (2014).
100. Nawaz, F. et al. The genotype of early-transmitting HIV gp120s promotes α4β7-reactivity, revealing α4β7+/CD4+ T cells as key targets in mucosal transmission. PLoS Pathog. 7, e1001301 (2011).
101. Wagner, N. et al. Critical role for β7 integrins in formation of the gut-associated lymphoid tissue. Nature 382, 366-370 (1996).
102. Perez, L. G., Chen, H., Liao, H. X. & Montefiori, D. C. Envelope glycoprotein binding to the α4β7 integrin complex is not a general property of most HIV-1 variants. J. Virol. 88, 10767-10777 (2014).
103. Richardson, S. I. et al. The sequence of the α4β7-binding motif on gp120 of transmitted/founder viruses contributes to the dependence on the integrin for HIV infection. AIDS Res. Hum. Retroviruses 30, A56 (2014).
104. Byrareddy, S. N. et al. Targeting αβ integrin reduces mucosal transmission of simian immunodeficiency virus and protects gut-associated lymphoid tissue from infection. Nat. Med. 20, 1397-1400 (2014).
105. Schnell, G., Price, R. W., Swanstrom, R. & Spudich, S. Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection. J. Virol. 84, 2395-2407 (2010).
106. Sturdevant, C. B. et al. Central nervous system compartmentalization of HIV-1 subtype C variants early and late in infection in young children. PLoS Pathog. 8, e1003094 (2012).
107. Del Prete, G. Q. et al. Molecularly tagged simian immunodeficiency virus SIVmac239 synthetic swarm for tracking independent infection events. J. Virol. 88, 8077-8090 (2014).
108. Coates, T. J., Richter, L. & Caceres, C. Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet 372, 669-684 (2008).
109. Wetmore, C. M., Manhart, L. E. & Wasserheit, J. N. Randomized controlled trials of interventions to prevent sexually transmitted infections: learning from the past to plan for the future. Epidemiol. Rev. 32, 121-136 (2010).
110. Gray, R. H. et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 369, 657-666 (2007).
111. Muessig, K. E. & Cohen, M. S. Advances in HIV prevention for serodiscordant couples. Curr. HIV/AIDS Rep. 11, 434-446 (2014).
112. Rodger, A. et al. HIV transmission risk through condomless sex if the HIV+ partner is on suppressive ART: PARTNER study. Top. Antivir. Med. 22, 24-25 (2014).
113. Smedley, J. et al. Tracking the luminal exposure and lymphatic drainage pathways of intravaginal and intrarectal inocula used in nonhuman primate models of HIV transmission. PLoS ONE 9, e92830 (2014).
114. Stieh, D. J. et al. Vaginal challenge with an SIV-based dual reporter system reveals that infection can occur throughout the upper and lower female reproductive tract. PLoS Pathog. 10, e1004440 (2014).
115. Haynes, B. F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. New Engl. J. Med. 366, 1275-1286 (2012).
116. Rolland, M. et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 490, 417-420 (2012).
117. Rolland, M. et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat. Med. 17, 366-371 (2011).
118. Roederer, M. et al. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature 505, 502-508 (2014).
119. Dolgin, E. Long-acting HIV drugs advanced to overcome adherence challenge. Nat. Med. 20, 323-324 (2014).
120. Koharudin, L. M. I. & Gronenborn, A. M. Antiviral lectins as potential HIV microbicides. Curr. Opin. Virol. 7, 95-100 (2014).
121. Ribeiro, R. M. et al. Estimation of the initial viral growth rate and basic reproductive number during acute HIV-1 infection. J. Virol. 84, 6096-6102 (2010).
122. Mellors, J. W. et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272, 1167-1170 (1996).
123. Fraser, C., Hollingsworth, T. D., Chapman, R., de Wolf, F. & Hanage, W. P. Variation in HIV-1 set-point viral load: epidemiological analysis and an evolutionary hypothesis. Proc. Natl Acad. Sci. USA 104, 17441-17446 (2007).
124. Fraser, C. et al. Virulence and pathogenesis of HIV-1 infection: an evolutionary perspective. Science 343, 1243727 (2014).
125. Hodcroft, E. et al. The contribution of viral genotype to plasma viral set-point in HIV infection. PLoS Pathog. 10, e1004112 (2014).
126. Tang, J. M. et al. HLA allele sharing and HIV type 1 viremia in seroconverting Zambians with known transmitting partners. AIDS Res. Hum. Retroviruses 20, 19-25 (2004).